KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Equity Ratio (2017 - 2025)

Bionano Genomics' Equity Ratio history spans 7 years, with the latest figure at 0.63 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 12.61% year-over-year to 0.63; the TTM value through Sep 2025 reached 0.63, up 12.61%, while the annual FY2024 figure was 0.46, 2.88% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.63 at Bionano Genomics, up from 0.6 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.97 in Q2 2021 and bottomed at 0.45 in Q4 2023.
  • The 5-year median for Equity Ratio is 0.79 (2023), against an average of 0.73.
  • The largest annual shift saw Equity Ratio soared 527.32% in 2021 before it plummeted 44.7% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.89 in 2021, then decreased by 9.28% to 0.81 in 2022, then tumbled by 44.7% to 0.45 in 2023, then grew by 2.88% to 0.46 in 2024, then skyrocketed by 36.52% to 0.63 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Equity Ratio are 0.63 (Q3 2025), 0.6 (Q2 2025), and 0.61 (Q1 2025).